Feminizing Leydig cell tumor: endocrine and incubation studies. 1987

P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun

A 32-year-old patient with a history of surgery for left gynecomastia four years previously presented with right gynecomastia; a tumor in the left testis proved to be a Leydig cell tumor. Preoperative investigations showed elevated but variable levels of plasma estradiol (E2) and estrone (E1), and reduced serum LH and FSH and plasma testosterone (T). After hCG stimulation, E2 response was increased and abnormally prolonged; T reached normal values, which has predictive value for a return to normal of post-operative T level. After left orchiectomy, gynecomastia regressed within a few days, gonadotropins increased by day 2, estrogens dropped by day 2 and were normal at day 7, T and 5 alpha-dihydrotestosterone dropped at day 2 but reached normal levels at day 16. Pathophysiology of these hormonal data are discussed. An incubation procedure with 3H testosterone showed an aromatase activity 21 times greater in the tumor than in normal peritumoral tissue, while the percentage of the volume occupied by Leydig cells was 34 times higher. This suggests that the aromatase activity of a single tumor cell is very similar to that of a normal Leydig cell. Furthermore, evidence of juxtatumoral Leydig cell hyperplasia in areas where the tumor was well encapsulated suggests the existence of a factor stimulating Leydig cell multiplication.

UI MeSH Term Description Entries
D007984 Leydig Cell Tumor Gonadal interstitial or stromal cell neoplasm composed of only LEYDIG CELLS. These tumors may produce one or more of the steroid hormones such as ANDROGENS; ESTROGENS; and CORTICOSTEROIDS. Clinical symptoms include testicular swelling, GYNECOMASTIA, sexual precocity in children, or virilization (VIRILISM) in females. Interstitial Cell Tumor,Interstitial Cell Tumors,Tumor, Interstitial Cell,Tumor, Leydig Cell,Tumors, Interstitial Cell
D008297 Male Males
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D006065 Gonadotropins, Pituitary Hormones secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR) that stimulate gonadal functions in both males and females. They include FOLLICLE STIMULATING HORMONE that stimulates germ cell maturation (OOGENESIS; SPERMATOGENESIS), and LUTEINIZING HORMONE that stimulates the production of sex steroids (ESTROGENS; PROGESTERONE; ANDROGENS). Pituitary Gonadotropins
D006177 Gynecomastia Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males. Adolescent Gynecomastia,Infant Gynecomastia,Male Breast Enlargement,Newborn Gynecomastia,Breast Enlargement, Male,Enlargement, Male Breast,Gynecomastia, Adolescent,Gynecomastia, Infant,Gynecomastia, Newborn
D006728 Hormones Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. Hormone,Hormone Receptor Agonists,Agonists, Hormone Receptor,Receptor Agonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D001141 Aromatase An enzyme that catalyzes the desaturation (aromatization) of the ring A of C19 androgens and converts them to C18 estrogens. In this process, the 19-methyl is removed. This enzyme is membrane-bound, located in the endoplasmic reticulum of estrogen-producing cells of ovaries, placenta, testes, adipose, and brain tissues. Aromatase is encoded by the CYP19 gene, and functions in complex with NADPH-FERRIHEMOPROTEIN REDUCTASE in the cytochrome P-450 system. CYP19,Cytochrome P-450 CYP19,Cytochrome P-450(AROM),Androstenedione Aromatase,CYP 19,CYP19 Protein,Cytochrome P450 19,Estrogen Synthase,Estrogen Synthetase,P450AROM,Aromatase, Androstenedione,Cytochrome P 450 CYP19,Protein, CYP19

Related Publications

P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
October 1984, Journal of surgical oncology,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
November 1977, Human pathology,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
April 1987, The Journal of clinical endocrinology and metabolism,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
January 1982, Ultrastructural pathology,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
January 1983, Ultrastructural pathology,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
June 1981, Schweizerische medizinische Wochenschrift,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
October 1985, Cancer,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
January 1967, Annales d'endocrinologie,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
January 2010, Journal of biomedicine & biotechnology,
P Valensi, and C Coussieu, and A Pauwels, and J R Attali, and J L Kemeny, and J Amouroux, and J Sebaoun
June 1989, Archivos espanoles de urologia,
Copied contents to your clipboard!